Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA.
about
Role of MR Imaging and FDG PET/CT in Selection and Follow-up of Patients Treated with Pelvic Exenteration for Gynecologic MalignanciesIntraoperative radiotherapy in gynaecological and genito-urinary malignancies: focus on endometrial, cervical, renal, bladder and prostate cancersThe value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration.Total pelvic exenteration for primary and recurrent malignancies.Prediction model for 30-day morbidity after gynecological malignancy surgeryOverall survival after pelvic exenteration for gynecologic malignancy.Surgical results of pelvic exenteration in the treatment of gynecologic cancer.Modified vertical rectus abdominis myocutaneous flap vaginal reconstruction: an analysis of surgical outcomes.Resection of the vaginal vault for vaginal recurrence of cervical cancer after hysterectomy and brachytherapy.Pelvic exenteration--reconsidering the procedure.Vaginal vault recurrences of endometrial cancer in non-irradiated patients - Radiotherapy or surgery.Total pelvic exenteration for gynecologic malignancies.Treatment options in recurrent cervical cancer (Review).Retrospective review of pelvic malignancies undergoing total pelvic exenteration.Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in KoreaThe role of palliative surgery in gynecologic cancer cases.Permanent interstitial re-irradiation with Au-198 seeds in patients with post-radiation locally recurrent uterine carcinoma.Outcome of patients with local recurrent gynecologic malignancies after resection combined with intraoperative electron radiation therapy (IOERT).Pelvic exenteration in gynecologic oncology: a single institution study over 20 yearsClinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with locally advanced cervical cancer treated with radiation or chemoradiation.The effect of body mass index on surgical outcomes and survival following pelvic exenterationSalvage interstitial brachytherapy based on computed tomography for recurrent cervical cancer after radical hysterectomy and adjuvant radiation therapy: case presentations and introduction of the technique.Pelvic exenteration: impact of age on surgical and oncologic outcomes.Pelvic exenteration for recurrent squamous cell carcinoma of the pelvic organs arising from the cloaca--a single institution's experience over 16 years.Should pelvic exenteration for symptomatic relief in gynaecology malignancies be offered?Initial experience of robotic anterior pelvic exenteration at a single institute.Laparoscopic salvage total pelvic exenteration: Is it possible post-chemo-radiotherapy?Primary vaginal reconstruction at the time of pelvic exenteration for gynecologic cancer: morbidity revisited.Proton Therapy for Vaginal Reirradiation.Morbidity and outcome of pelvic exenteration in locally advanced pelvic malignanciesRole of preoperative MR imaging in the evaluation of patients with persistent or recurrent gynaecological malignancies before pelvic exenteration.Clinical outcome of pelvic exenteration in patients with advanced or recurrent uterine cervical cancer.Radical hysterectomy after radiotherapy for recurrent or persistent cervical cancer.Factors affecting hospital length of stay following pelvic exenteration surgery.Salvage Surgery for Cervical Cancer Recurrences.Pelvic exenteration for the treatment of locally advanced colorectal and bladder malignancies in the modern era.Optimal cutoff level of serum squamous cell carcinoma antigen to detect recurrent cervical squamous cell carcinoma during post-treatment surveillance.
P2860
Q28088565-87107546-2A99-40C8-B262-408F80CDA2DDQ28559812-DCEB2F06-17D8-4F27-BA86-7070FA13B7DAQ30584396-85A31356-18E5-4C0E-B0C4-2A42758247DFQ33440719-953B57B8-C8E9-4264-BB05-F1B952A01155Q33751884-38CF7ADF-3A6E-41FF-AA99-932AF662BC60Q34160897-A68AB07F-56CE-4E9B-A785-A7CBF50A3478Q34203674-A8F0EC4E-F5EB-4B15-A523-A19DC9C9762FQ34687881-56EB9282-3599-43CC-B956-C3117468616AQ35293153-1DC7D02B-B1E8-4D05-9BDA-1D02DF08628EQ35349856-86BF720E-508C-4A89-A254-C387B07ECDDAQ35614157-027D874B-4539-4D31-88E0-784C2F6AD650Q36036525-7E0BA2F7-3A6F-4429-A051-77FB5DD18EC4Q36216582-1531698A-9AE9-4970-BB8A-B0D31C652274Q36300388-0E629F08-AC38-42C1-A050-E514E8A81EB3Q36313275-62F2720C-21FC-4CE6-AA78-1DA46DC72EC3Q36565651-A9FC94B0-16F8-4555-82E4-4C64AA181B27Q36661388-B3A27701-3E68-4C45-AAB9-51256B9533F9Q36701305-A8BA2294-11BB-48A9-8476-B3E2FDF5ED80Q36920531-BBE6B833-042F-4B6C-AEB6-236144B651DAQ37121118-687EED0D-CBB4-4702-B163-ED1D54B5CC74Q37362963-892E68BD-664F-41EE-92F1-57BECA63CE23Q37424411-065B97DF-7C74-4B8F-9435-46062D212E98Q37606647-278FDF5E-8802-4FA2-A3BF-59315CB0DFD7Q38110100-4D6A0EB4-C699-40FF-A0AF-B84F13E15285Q38136485-341D77E1-2B06-480E-AD07-7C3A9219BBAFQ38208503-1C4F5B20-140F-4E8F-A85B-0C8AF3B94EEFQ39736451-1AC804AC-D839-46D7-8E89-62AEAD8DF306Q40406774-56513EAB-03D6-4D34-9F92-386E2B7160CEQ42281315-46381329-ACB8-4FC1-8227-D72D54040088Q42325879-ED8BDC32-DC72-44B6-B1A0-82141E039C74Q43725295-99A9D8F7-AC28-4F69-8441-81A927B2DCC7Q43771275-9F91E36F-447D-4CA7-9FBF-BC0DDA1FF23DQ47310104-61668AAA-A889-45ED-8CE2-8AD01618267CQ48169870-97329DF5-153E-4C56-A4D1-015B795B6C92Q50621493-B1A3DE59-9101-49A2-9EA8-E74E2CF7FE87Q54644555-E4E9D812-96EE-4B7C-9F61-46AA8CF00967Q54971998-8340AA57-D1E8-4DE9-B4A3-DE996CBEF170
P2860
Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Pelvic exenteration for recurr ...... he 45-year experience at UCLA.
@ast
Pelvic exenteration for recurr ...... he 45-year experience at UCLA.
@en
type
label
Pelvic exenteration for recurr ...... he 45-year experience at UCLA.
@ast
Pelvic exenteration for recurr ...... he 45-year experience at UCLA.
@en
prefLabel
Pelvic exenteration for recurr ...... he 45-year experience at UCLA.
@ast
Pelvic exenteration for recurr ...... he 45-year experience at UCLA.
@en
P2093
P1433
P1476
Pelvic exenteration for recurr ...... he 45-year experience at UCLA.
@en
P2093
Candace Howe
Jonathan S Berek
Leo D Lagasse
Neville F Hacker
P304
P356
10.1016/J.YGYNO.2005.05.034
P407
P577
2005-10-01T00:00:00Z